VANECK PHARMACEUTICAL ETF (PPH) Stock News
NASDAQ:PPH - Nasdaq - US92189F6925 - ETF - Currency: USD
PPH Latest News and Analysis
VanEck Announces Year-End Distributions for VanEck Equity ETFs
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss drugs, Ozempic and Wegovy.
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management.
The Top 3 ETFs to Buy in March 2024
Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside.
Big Pharma earnings in spotlight amid positive sentiment
Barclays and UBS preview Q4 2023 earnings for bigpharma, with Eli Lilly (LLY), AbbVie (ABBV), Merck (MRK) and Amgen (AMGN) among their key picks. Read more here.
Pfizer stock: What to expect in 2024 (NYSE:PFE)
Pfizer's (PFE) stocks has lost ~44% in 2023 due to concerns over the demand for its COVID-19 products. Read what to expect from Pfizer (PFE) in 2024.
Gilead stock in 2024: What to expect? (NASDAQ:GILD)
Gilead Sciences (GILD) has outperformed other pandemic-era favorites in 2023, with only a 6% loss in 2023. Read what to expect from Gilead (GILD) in 2024.
Why is big pharma unmoved despite Medicare pricing threat?
Read why big pharma stocks ended the week in green even after Medicare unveiled the first ten drugs targeted for the initial round of pricing talks. Read more here.
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market.
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharma stocks experienced an abysmal first half due to various factors. Rotatio...
What is behind big pharma's underperformance? (NASDAQ:PPH)
With a looming patent cliff ahead, pharma is trailing the S&P 500 amid regulatory challenges against acquisitions and Medicare drug pricing. Read more here..
Better Buy for 2022: Merck vs. AstraZeneca
Given rising investments and medical breakthroughs, the dire need for COVID-19 vaccines and pills, and the pressing need to treat several other diseases, the pharmaceutical industry should continue growing this year and beyond. We think prominent companies in this space, Merck & Co. (MRK) and AstraZeneca (AZN), are well-positioned to capitalize on the industry tailwinds. But which of these stocks is a better buy now? Read more to learn our view.
Covid Has Boosted the Healthcare Sector. Pfizer Stock Is a Prime Example.
With the Delta variant of coronavirus shaking things up, the healthcare sector has started gaining momentum.
7 Pharmaceutical Stocks That Could Get a Covid Hangover
Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now.
The FTC Is Taking a More Aggressive Approach Toward Pharmaceutical M&A
The Federal Trade Commission warned it intends to take an aggressive approach to “anticompetitive pharmaceutical mergers.\
Big Pharma Battled the Pandemic. The Stocks Are Cheap.
Huge cash flows and strong pipelines: Here are the drugmakers to consider.
Announcing VanEck Vectors ETFs’ December 2020 Distributions
Announcing VanEck Vectors ETFs’ September 2020 Distributions
